Pharmaust Investor Update, page-19

Thanks for bringing Investor webinar NZT, I went listened twice the Q&A session at the end of the video. My uptake are:

• Funding is assured and has variety of options available (I wish JC provided little bit more depth on this area)
• The technical advisory board is still intact (Prof Leonard van den Berg, Dr Sabrina Paganoni; Dr Melanie Quintana and Dr Christian Freitag)
• Previous CEO, Dr. MT is still working full time and providing full support to JC. Is there substance to his permanent return to PAA (possible?)
• All patents are still intact and valid until 2030, and there will additional news on US patent at the end of the year.

I wish Dr MT returns to PAA board permanently as he is eloquent presenter who brings energy and confidence. I believe the tussle between the old board and MT started after his media coverage on channel 7 interview (WA) where he presented a targeted sales figure which favoured the SP. After which PAA release a media clarification that those figures do not have reasonable basis. I understand Dr MT is very focused on best interest of shareholders and should return to PAA permanently.